News | February 08, 2022
GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage that can potentially prevent viral entry, regardless of vaccination or infection status
Corbevax is administered through an intramuscular route with two doses scheduled 28 days apart and is stored between 2 degrees celsius to 8 degrees celsius
Ascent Meditech has set benchmarks in introducing pain management products in India. The company has embarked on a new marketing campaign as it plans to enter new markets. Rajiv Mistry, Founder & Managing Director, Ascent Group shares his perspective with Thomas C Thottathil on the road ahead for the company and industry
The vaccine will be priced at Rs. 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
Subscribe To Our Newsletter & Stay Updated
